Items where authors include "Tappenden, P."
Up a levelArticle
Jin, H. orcid.org/0000-0002-3872-3998, Tappenden, P. orcid.org/0000-0001-6612-2332, Ling, X. et al. (2 more authors) (2023) A systematic review of whole disease models for informing healthcare resource allocation decisions. PLOS ONE, 18 (9). e0291366. ISSN 1932-6203
Wildman, M.J., O'Cathain, A., Maguire, C. et al. (14 more authors) (2022) Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax, 77 (5). pp. 461-469. ISSN 0040-6376
Murphy, P., Glynn, D., Dias, S. et al. (11 more authors) (2022) Modelling approaches for histology-independent cancer drugs to inform NICE appraisals : a systematic review and decision-framework. Health Technology Assessment, 25 (76). pp. 1-228. ISSN 1366-5278
Wildman, M.J., O’Cathain, A., Hind, D. orcid.org/0000-0002-6409-4793 et al. (25 more authors) (2021) An intervention to support adherence to inhaled medication in adults with cystic fibrosis : the ACtiF research programme including RCT. Programme Grants for Applied Research, 9 (11). pp. 1-146. ISSN 2050-4322
Srivastava, T. orcid.org/0000-0002-5961-9348, Latimer, N.R. orcid.org/0000-0001-5304-5585 and Tappenden, P. orcid.org/0000-0001-6612-2332 (2021) Estimation of transition probabilities for state-transition models : a review of NICE appraisals. PharmacoEconomics, 39 (8). pp. 869-878. ISSN 1170-7690
Jin, H., Tappenden, P. orcid.org/0000-0001-6612-2332, MacCabe, J.H. et al. (3 more authors) (2021) Cost and health impacts of adherence to the National Institute for Health and Care Excellence schizophrenia guideline recommendations. The British Journal of Psychiatry, 218 (4). pp. 224-229. ISSN 0007-1250
Burt, R.K., Tappenden, P., Balabanov, R. et al. (4 more authors) (2021) The cost effectiveness of immunoglobulin vs. hematopoietic stem cell transplantation for CIDP. Frontiers in Neurology, 12. 645263.
Cooper, K. orcid.org/0000-0002-7702-8103, Tappenden, P., Cantrell, A. et al. (1 more author) (2020) A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer. British Journal of Cancer, 123 (11). pp. 1686-1696. ISSN 0007-0920
Burt, R.K., Tappenden, P. orcid.org/0000-0001-6612-2332, Han, X. et al. (5 more authors) (2020) Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. Multiple Sclerosis and Related Disorders, 45. 102404. ISSN 2211-0348
Jin, H., Tappenden, P. orcid.org/0000-0001-6612-2332, Robinson, S. et al. (3 more authors) (2020) Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia. PLOS ONE, 15 (7). e0234996.
Jin, H., Tappenden, P. orcid.org/0000-0001-6612-2332, Robinson, S. et al. (4 more authors) (2020) A systematic review of economic models across the entire schizophrenia pathway. PharmacoEconomics, 38 (6). pp. 537-555. ISSN 1170-7690
Jin, H., Tappenden, P. orcid.org/0000-0001-6612-2332, MacCabe, J.H. et al. (2 more authors) (2020) Evaluation of the cost-effectiveness of services for Schizophrenia in the UK across the entire care pathway in a single whole-disease model. JAMA network open, 3 (5). e205888.
Alshreef, A. orcid.org/0000-0003-2737-1365, Latimer, N. orcid.org/0000-0001-5304-5585, Tappenden, P. et al. (4 more authors) (2019) Statistical methods for adjusting estimates of treatment effectiveness for patient nonadherence in the context of time-to-event outcomes and health technology assessment: A systematic review of methodological papers. Medical Decision Making, 39 (8). pp. 910-925. ISSN 0272-989X
Harnan, S. orcid.org/0000-0002-9318-9206, Tappenden, P. orcid.org/0000-0001-6612-2332, Cooper, K. orcid.org/0000-0002-7702-8103 et al. (7 more authors) (2019) Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment, 23 (30). ISSN 1366-5278
Tappenden, P. orcid.org/0000-0001-6612-2332, Carroll, C. orcid.org/0000-0002-6361-6182, Hamilton, J. orcid.org/0000-0003-3326-9842 et al. (5 more authors) (2019) Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Health Technology Assessment, 23 (8). pp. 1-144. ISSN 1366-5278
Tappenden, P. orcid.org/0000-0001-6612-2332, Carroll, C. orcid.org/0000-0002-6361-6182, Stevens, J. orcid.org/0000-0002-9867-7209 et al. (5 more authors) (2019) Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 37 (1). pp. 7-18. ISSN 1170-7690
Tappenden, P. orcid.org/0000-0001-6612-2332, Simpson, E. orcid.org/0000-0001-7353-5979, Hamilton, J. et al. (5 more authors) (2018) Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. ISSN 1170-7690
Bermejo, I. orcid.org/0000-0001-9105-8088, Tappenden, P. and Youn, J.H. (2017) Replicating Health Economic Models: Firm Foundations or a House of Cards? Pharmacoeconomics, 35. pp. 1113-1121. ISSN 1170-7690
Bermejo, I., Tappenden, P. orcid.org/0000-0001-6612-2332 and Youn, J.H. (2017) Response to ‘Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”’. PharmacoEconomics, 35 (11). pp. 1189-1190. ISSN 1170-7690
Tappenden, P. orcid.org/0000-0001-6612-2332, Carroll, C. orcid.org/0000-0002-6361-6182, Stevens, J.W. orcid.org/0000-0002-9867-7209 et al. (7 more authors) (2017) Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35 (8). pp. 805-815. ISSN 1170-7690
Uttley, L. orcid.org/0000-0003-4603-9069, Whyte, S., Gomersall, T. et al. (4 more authors) (2017) Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics , 35 (7). pp. 717-726. ISSN 1170-7690
Tappenden, P. orcid.org/0000-0001-6612-2332, Sadler, S. orcid.org/0000-0001-5935-8507 and Wildman, M. (2017) An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis. PharmacoEconomics, 35 (6). pp. 647-659. ISSN 1170-7690
Carroll, C., Kaltenthaler, E. orcid.org/0000-0002-6185-8321, Hill-McManus, D. et al. (6 more authors) (2017) The type and impact of Evidence Review Group (ERG) exploratory analyses in the NICE Single Technology Appraisal (STA) process. Value in Health, 20 (6). pp. 785-791. ISSN 1098-3015
Atkin, W., Brenner, A., Martin, J. et al. (16 more authors) (2017) The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations. Health Technol Assess, 21 (25). pp. 1-536. ISSN 1366-5278
Carroll, C. orcid.org/0000-0002-6361-6182, Tappenden, P. orcid.org/0000-0001-6612-2332, Rafia, R. orcid.org/0000-0002-6914-1990 et al. (6 more authors) (2017) Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35 (5). pp. 537-547. ISSN 1170-7690
Harnan, S.E., Essat, M. orcid.org/0000-0003-2397-402X, Gomersall, T. et al. (4 more authors) (2017) Exhaled nitric oxide in the diagnosis of asthma in adults: a systematic review. Clinical and Experimental Allergy, 47 (3). pp. 410-429. ISSN 0954-7894
Kaltenthaler, E., Carroll, C., Hill-McManus, D. et al. (6 more authors) (2016) Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process. PharmacoEconomics. ISSN 1170-7690
Goodall, M., Tosh, J., Alshreef, A.O. orcid.org/0000-0003-2737-1365 et al. (1 more author) (2016) Conceptual Modelling for Cost-Effectiveness Analysis of Intravitreal Therapy with Ranibizumab, Aflibercept or Bevacizumab for Macular Oedema Due to Central Retinal Vein Occlusion. Value in Health, 19 (7). A366. ISSN 1524-4733
Tappenden, P. orcid.org/0000-0001-6612-2332, Ren, S., Archer, R. et al. (6 more authors) (2016) A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. PharmacoEconomics, 34 (10). pp. 1023-1038. ISSN 1170-7690
Tappenden, P. orcid.org/0000-0001-6612-2332, Harnan, S. orcid.org/0000-0002-9318-9206, Ren, S. et al. (6 more authors) (2016) Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. ISSN 1170-7690
Thokala, P., Simpson, E., Tappenden, P. et al. (4 more authors) (2016) Ledipasvir-Sofosbuvir for treating Chronic Hepatitis C: A NICE Single Technology Appraisal - An Evidence Review Group Perspective. PharmacoEconomics, 34 (8). pp. 741-750. ISSN 1170-7690
Archer, R., Tappenden, P., Ren, S. et al. (8 more authors) (2016) Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technoogyl Assessment, 20. 39. ISSN 1366-5278
Kaltenthaler, E. orcid.org/0000-0002-6185-8321, Carroll, C., Hill-McManus, D. et al. (6 more authors) (2016) The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis. Health Technology Assessment, 20. 26. ISSN 1366-5278
Essat, M., Harnan, S., Gomersall, T. et al. (5 more authors) (2016) Fractional exhaled nitric oxide for the management of asthma in adults: Systematic review. European Respiratory Society. ISSN 0903-1936
Essat, M., Tappenden, P., Ren, S. et al. (5 more authors) (2015) Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. ISSN 1170-7690
Harnan, S.E., Tappenden, P., Essat, M. et al. (6 more authors) (2015) Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath. Health Technology Assessment, 19 (82). ISSN 1366-5278
Campbell, F., Holmes, M., Everson-Hock, E. et al. (5 more authors) (2015) A systematic review and economic evaluation of exercise referral schemes in primary care: a short report. Health Technology Assessment, 19 (60). ISSN 1366-5278
Latimer, N. R. orcid.org/0000-0001-5304-5585, Carroll, C., Wong, R. orcid.org/0000-0002-4536-4794 et al. (3 more authors) (2014) Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal. PharmacoEconomics, 32 (12). pp. 1171-1183. ISSN 1170-7690
Kaltenthaler, E., Essat, M., Tappenden, P. et al. (1 more author) (2014) Identification and review of cost-effectiveness model parameters: a qualitative study. International Journal of Technology Assessment in Health Care, 30 (3). pp. 333-340. ISSN 0266-4623
Ciani, O., Cantrell, A. orcid.org/0000-0003-0040-9853, Davis, S. orcid.org/0000-0002-6609-4287 et al. (6 more authors) (2014) Validation of Surrogate Endpoints in Advanced Solid Tumors: Systematic Review of Statistical Methods, Results, and Implications for Policy Makers. International Journal of Technology Assessment in Health Care, 30 (3). pp. 312-324. ISSN 0266-4623
Stevenson, M., Tappenden, P. and Squires, H. (2014) Methods for handling uncertainty within pharmaceutical funding decisions. International Journal of Systems Science, 45 (1). pp. 60-68. ISSN 0020-7721
Rathbone, J., Kaltenthaler, E., Richards, A. et al. (3 more authors) (2013) A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open, 3 (11). e003573. ISSN 2044-6055
Kaltenthaler, E., Tappenden, P. and Paisley, S. (2013) Reviewing the evidence to inform the population of cost-effectiveness models within health technology assessments. Value in Health, 16 (5). pp. 830-836. ISSN 1098-3015
Sharp, L., Walsh, C., Whyte, S. et al. (8 more authors) (2013) Reply: cost-effectiveness of population-based screening for colorectal cancer. British Journal of Cancer, 108 (5). pp. 1211-1212. ISSN 0007-0920
Sharp, L., Tilson, L., Whyte, S. et al. (8 more authors) (2013) Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland. BMC Health Services Research, 13 (105). ISSN 1472-6963
Sharp, L., Tilson, L., Whyte, S. et al. (8 more authors) (2012) Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy. British Journal of Cancer , 106 (5). pp. 805-816. ISSN 0007-0920
Tappenden, P., Glynne-Jones, R., Shorthouse, A. et al. (3 more authors) (2012) Colorectal cancer and its detection, diagnosis, treatment and follow-up: disease and treatment pathways. HEDS Discussion Paper 12/09. (Unpublished)
Tappenden, P. (2012) Conceptual modelling for health economic model development. HEDS Discussion Paper 12/05. (Unpublished)
Kaltenhaler, E., Tappenden, P. and Paisley, S. (2012) Reviewing the evidence used in cost-effectiveness models in health technology assessment: a qualitative investigation of current concerns and future research priorities. HEDS Discussion Paper 12/01. (Unpublished)
Oakley, J.E., Brennan, A., Tappenden, P. et al. (1 more author) (2010) Simulation sample sizes for Monte Carlo partial EVPI calculations. Journal of Health Economics, 29 (3). pp. 468-477. ISSN 0167-6296
Pickin, M., Cooper, C.L., Chater, T. et al. (9 more authors) (2009) The multiple sclerosis risk sharing scheme monitoring study - early results and lessons for the future. BMC Neurology, 9. Art. No.1. ISSN 1471-2377
Karnon, J., McIntosh, A., Dean, J. et al. (9 more authors) (2008) Modelling the expected net benefits of interventions to reduce the burden of medication errors. Journal of Health Services Research and Policy, 13 (2). pp. 85-91. ISSN 1355-8196
Karnon, J., McIntosh, A., Dean, J. et al. (9 more authors) (2007) A prospective hazard and improvement analytic approach to predicting the effectiveness of medication error interventions. Safety Science, 45 (4). pp. 523-539. ISSN 0925-7535
Karnon, J., Goyder, E., Tappenden, P. et al. (4 more authors) (2007) A review and critique of modelling in priortising and designing screening programmes. Health Technology Assessment , 11 (52). pp. 1-166.
Eggington, S., Tappenden, P., Pandor, A. et al. (5 more authors) (2006) Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. British Journal of Cancer, 95 (9). 1195 - 1201. ISSN 0007-0920
Cooper, N.J., Claxton, K. orcid.org/0000-0003-2002-4694, Chilcott, J. et al. (4 more authors) (2003) Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ. pp. 522-525. ISSN 1756-1833
Monograph
Whyte, S., Harnan, S., Scope, A. et al. (8 more authors) (2012) Early awareness interventions for cancer: Colorectal cancer. Report. Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) (EEPRU 004). Policy Research Unit in Economic Evaluation of Health and Care Interventions
Pandor, A., Egginton, S., Paisley, S. et al. (2 more authors) (2006) The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. Technical Report. Gray Publishing , Tunbridge Wells.
Tappenden, P., Brazier, J. and Ratcliffe, J. (2006) Does the National Institute for Health and Clinical Excellence take account of factors such as uncertainty and equity as well as incremental cost-effectiveness in commissioning health care services? A binary choice experiment. Discussion Paper. (Unpublished)
Claxton, K., Eggington, S., Ginnelly, L. et al. (5 more authors) (2005) A pilot study of value of information analysis to support research recommendations for NICE. Research Report. CHE Research Paper (4). Centre for Health Economics , York, UK.
Tappenden, P., Chilcott, J., Egginton, S. et al. (2 more authors) (2004) Methods for expected value of information analysis in complex health economic models: developments on the health economics of beta interferon and glatiramer acetate for multiple sclerosis. Technical Report. Gray Publishing , Tunbridge Wells.
Chilcott, J., Brennan, A., Booth, A. et al. (2 more authors) (2003) The role of modelling in prioritising and planning clinical trials. Technical Report. Gray Publishing , Tunbridge Wells.
Chilcott, J., Lloyd Jones, M., Wight, J. et al. (4 more authors) (2003) A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. Technical Report. Core Research , Alton.
Richards, R.G., Simpson, F.C., Beard, S.M. et al. (1 more author) (2002) A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Technical Report. Core Research , Alton.
Chilcott, J., Wight, J., Lloyd Jones, M. et al. (1 more author) (2001) The clinical effectiveness and cost-effectiveness of pioglitazone in type 2 diabetes mellitus: a rapid and systematic review. Technical Report. Core Research , Alton.
Other
Wildman, M., Hutchings, M., Arden, M. et al. (10 more authors) (2018) Development and evaluation of an intervention to support adherence to treatment in adults with Cystic Fibrosis : a randomised controlled trial and parallel process evaluation protocol. Sheffield Teaching Hospitals NHS Foundation Trust.